Novartis and GSK Trade Assets
Portfolio swaps between Novartis and GSK involve oncology, vaccines, and consumer products.
Novartis and GlaxoSmithKline plc (GSK) have announced a major swap of assets in which Novartis will acquire the oncology products business of GSK and divest its vaccines business (excluding flu) to GSK. In addition, the two companies will create a joint venture, combining their consumer divisions.
Separately, Novartis announced an agreement with Eli Lilly and Company to divest the Animal Health Division.
Novartis will make a $14.5 billion payment and up to $1.5 billion contingent on a development milestone for the GSK oncology products. Under the terms of the transaction, Novartis would have opt-in rights to GSK's current and future oncology R&D pipeline.
Novartis has agreed to divest its Vaccines business to GSK, currently excluding its flu business, for $7.1 billion ($5.25 billion upfront and up to $1.8 billion in milestones). In addition, Novartis reports it has initiated a separate sales process for its flu business.
Novartis and GSK have agreed to create a consumer healthcare business through a joint venture between Novartis OTC and GSK Consumer Healthcare. Novartis will own a 36.5% share of the joint venture and will have four of eleven seats on the joint venture's Board.
"The transactions mark a transformational moment for Novartis. They focus the company on leading businesses with innovation power and global scale. They also improve our financial strength, and are expected to add to our growth rates and margins immediately," said Joseph Jimenez, CEO of Novartis in a company statement.
"This proposed 3-part transaction accelerates our strategy to generate sustainable, broadly sourced sales growth and improve long-term earnings. Opportunities to build greater scale and combine high quality assets in Vaccines and Consumer Healthcare are scarce. With this transaction we will substantially strengthen two of our core businesses and create significant new options to increase value for shareholders," said Sir Andrew Witty, Chief Executive Officer, GSK in a statement.
The Lilly/Novartis transaction is expected to close by the end of the first quarter of 2015 and the GSK/Novartis transaction is expected to close during the first half of 2015.
Sources:
NovartisGlaxoSmithKline
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
